The U.S. Food and Drug Administration (FDA) approved a new “deep-learning” version of Hyperfine’s portable MRI machine, the Guilford-based company announced Monday.
Deep learning (DL), a type of machine learning and artificial intelligence, powers the company’s advanced image reconstruction technology, which allows for better image quality and more diagnostic value for Hyperfine’s Swoop portable MRI, according to the company.
Hyperfine President CEO Dave Scott said, “Improved image quality through artificial intelligence, paired with the lower cost and bedside capabilities of Swoop, are enabling greater access to high-quality MR imaging for patients, regardless of income, resources or location.”
Dr. Fady Charbel, head of neurosurgery at the University of Illinois of Chicago, said, “With the integration of deep learning-based image reconstruction, clinicians can now visualize anatomy and pathology more clearly and with increased confidence enabling diagnosis in a more expeditious fashion, critical for the treatment of acute neurological conditions.”
Wheeled to a patient’s bedside and controlled via an iPad, the Swoop Portable MR Imaging System allows clinicians to quickly scan, diagnose and treat patients in various clinical settings. With the new DL technology, the device can provide high-quality images, in less time and with less patient discomfort than traditional MRI machines.
Earlier this month, Hyperfine announced it had won a $3.3 million Bill & Melinda Gates Foundation grant to expand the use of Swoop in underdeveloped countries.
Entrepreneur Jonathan Rothberg founded Hyperfine in 2014. Another Rothberg-founded company, Detect, plans to market a ground-breaking new test for COVID-19 starting in December.
Hyperfine went public in July, combining with brain-monitoring firm Liminal Sciences and HealthCor Catalio Acquisition Corp., a healthcare-focused SPAC, in a deal valued at $580 million.
Contact Liese Klein at lklein@newhavenbiz.com.
